PLYMOUTH MEETING, Pa., April 21, 2015 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (Nasdaq:INO)
announced today that it has initiated a phase I trial to evaluate
Inovio's DNA immunotherapy in patients who are chronically infected with
hepatitis B. In 2013, Roche and Inovio entered into a partnership to
co-develop and commercialize Inovio's hepatitis B immunotherapy. This
trial initiation triggers a $3 million milestone payment from Roche to
Inovio.
This phase I, randomized, open-label, active-controlled, dose
escalation study will evaluate the safety, tolerability, and
immunogenicity of Inovio's hepatitis B immunotherapy, INO-1800, alone or
in combination with INO-9112, Inovio's IL-12-based immune activator.
This international study will enroll patients in the United States and
Asia Pacific region with a primary endpoint of safety and tolerability
of the therapy. The secondary endpoints will evaluate the cellular and
humoral immune response to INO-1800 and investigate the therapy's effect
on several viral and antiviral parameters. All trial subjects are also
medicated with standard-of-care antiviral therapies.
Labels: IL-12-based immune activator, INO-1800, INO-9112, Inovio